Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | OSBP | P22059 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.41 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19272838 | 1.00 | POLA1 (0.48) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL14652823 | 1.00 | POLA1 (0.48) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL19152812 | 1.00 | POLA1 (0.48) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL4546173 | 1.00 | POLA1 (0.48) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL15959349 | 0.99 | POLA1 (0.48) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL837589 | 0.97 | POLA1 (0.45) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL16421244 | 0.96 | POLA1 (0.44) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL22147380 | 0.96 | PLA2G2A (0.46) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL16449390 | 0.96 | POLA1 (0.46) | POLA1CYP46A1PLA2G2AAPPNR1H3 | |
| SCHEMBL24141990 | 0.96 | POLA1 (0.45) | POLA1CYP46A1PLA2G2AAPPNR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029338-B2 | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029338-B2 | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120270921-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus | ALNYLAM PHARMACEUTICALS, INC. | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270921-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus | PLIN5, DDX39B, EIF2AK2 | POLA1 1218/4885CYP46A1 1498/4885PLA2G2A 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.